v3.26.1
Intangible Assets (Tables)
 12 Months Ended
Dec. 31, 2025
Intangible Assets [Abstract]  
Schedule of Following Amounts in Accordance with the Following Milestones

According to the 3D Global License Agreement, YD Bio is obligated to pay the following amounts in accordance with the following milestones:

  

Item  Milestones  Milestone
License Fees
(USD)
1. Development of corneal Limbal Stem Cell (“LSC”) Cell Source   
1   Application with Medical Center for Clinical Specimens Collection  480,000
2   SOP Document for Technique of Separating LSC Specimens  230,000
3   LSC Cell Analysis/Assessment Report  330,000
2. Establishment of LSC Master Cell Banks   
1   SOP Document for LSC Amplification  230,000
2   SOP Document for LSC Cryopreservation  280,000
3. Cell Stability Examination of LSC   
1   Stability Examination Report of Master cell  420,000
2   Stability Examination Report of Working cell  420,000
4. Raw Material Development of LSC Exosomes   
1   SOP Document of Exosomes Purification Process  230,000
2   Specification Analysis/Examination Report of Exosomes Characterization  200,000
3   SOP Document of Mass Production Process of Exosomes Raw Material  370,000
4   Three Batches of Trial Production Document of Exosomes Raw Material  300,000
5   Safety Verification Report (animal testing) of Exosomes Raw Material  310,000
5. LensMate Eye Buffer LensMate   
1   Product Consignment Development Agreement  100,000
2   U.S. Food and Drug Administration (“FDA”) Approval for Type I Medical Material Certification  80,000
3   Sale Certification of US OTC  20,000
Schedule of Intangible Assets

Intangible assets consist of the following:

 

   December 31,
2025		   December 31,
2024		 
Licensed to Patents and Know-how        
3D Global Patent  $985,710   $942,450 
EG BioMed Patent   1,914,000    1,830,000 
Less: accumulated amortization   (289,971)   (92,415)
Total  $2,609,739   $2,680,035 
Schedule of Estimated Amortization The estimated amortization is as follows:
As of December 31, 2025  Estimated
amortization
expense		 
For the year ended December 31, 2026  $193,314 
For the year ended December 31, 2027   193,314 
For the year ended December 31, 2028   193,314 
For the year ended December 31, 2029   193,314 
For the year ended December 31, 2030   193,314 
Thereafter   1,643,169 
Total  $2,609,739